GlassScriptPhysician profile
Insoo Om
NPI 1538364989
$11,700.54
in general payments reported to CMS, 2019-2025
23 companies · $3,131 in 2025
The $3,131 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $998 · 2022: $1,970 · 2023: $2,360 · 2024: $3,242 · 2025: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,324 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,323.99 |
| Education | $409.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,520.76 | 2021-2025 | |
| Janssen Biotech, INC. | $1,487.26 | 2022-2025 | Tremfya |
| Ucb, INC. | $1,399.01 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $1,319.00 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $1,301.93 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $844.78 | 2023-2025 | Zoryve |
| Genzyme Corporation | $758.09 | 2021-2025 | |
| Incyte Corporation | $610.92 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $516.50 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $496.48 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Pfizer INC. | $424.67 | 2021-2024 | |
| Organon LLC | $240.31 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $194.87 | 2023-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $112.77 | 2022 | |
| Cipher Pharmaceuticals US LLC | $107.42 | 2025 | Natroba, Spinosad |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Botanix Sb INC | $63.22 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $57.10 | 2023 | |
| Galderma Laboratories, L.P. | $47.64 | 2025 | Nemluvio |
| Epi Health, LLC | $46.22 | 2022 | |
| Lilly USA, LLC | $29.37 | 2025 | Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.03 | 2023 | Cyltezo |
| Almirall LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Insoo Om listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.